Belsomra (Suvorexant) Cost in Ohio: Prices, Insurance, and Savings in 2026

Belsomra (generic name suvorexant) is an FDA-approved dual orexin receptor antagonist (DORA), a Schedule IV controlled substance prescribed for insomnia. There is no FDA-approved generic version of suvorexant as of this writing (2026), so patients in Ohio choose among the brand-name product, a compounded version made under a valid prescription, or an alternative sleep medication.

The direct answer: Belsomra's manufacturer list price is far higher than what most Ohio patients actually pay, because insurance formulary tier, manufacturer savings programs, and pharmacy discount cards each change the out-of-pocket amount independently. There is no single "Ohio price" for Belsomra. What is established is that Belsomra requires a prescription, is not currently available as an FDA-approved generic, and that Ohio Medicaid does not treat it as a preferred formulary drug for uncomplicated insomnia. What is not established, and what this page cannot responsibly assert, is a precise current cash price or a specific insurer's copay tier, because both change frequently and were not independently verified against a dated primary source for this draft.

What actually drives the price you pay

Three separate numbers get conflated in most cost articles: the manufacturer's list price (wholesale acquisition cost), the cash price a specific pharmacy charges after any discount card is applied, and the copay an insured patient owes after formulary tier and deductible status. These numbers can differ by hundreds of dollars for the same tablet on the same day. A list price figure from Merck's pricing disclosures is a starting point, not a prediction of what an Ohio pharmacy will actually charge, and cash prices reported by discount platforms change frequently enough that a specific dollar figure printed in an article can be outdated within weeks.

Because this draft cannot independently verify a specific current cash price, insurer copay range, or Ohio Medicaid preferred drug list entry against a dated primary source, we are not printing exact dollar figures here. Readers should get a live price quote from at least two or three Ohio pharmacies (chain and independent) and check their own plan's formulary tool before assuming any number, including numbers from other websites, is current.

Does Ohio Medicaid cover Belsomra?

Ohio Medicaid, like many state Medicaid programs, tends to place brand-name sleep medications behind generic sedative-hypnotics (such as zolpidem or eszopiclone) on its preferred drug list, and prior authorization is commonly required for non-preferred brand drugs. Whether Belsomra is covered for a given Ohio Medicaid enrollee, and under what clinical conditions, depends on the current preferred drug list published by the Ohio Department of Medicaid or the enrollee's managed care plan. That list is revised periodically, so a specific restriction described here as fixed (for example, tying coverage to a particular comorbidity) would be a claim this draft cannot verify from a primary Ohio Medicaid document, and it has been removed rather than repeated as fact.

If an Ohio Medicaid enrollee needs a DORA specifically, for example because of a documented adverse reaction to a benzodiazepine receptor agonist, the standard mechanism is a prior authorization request from the prescriber, with an appeal available through the plan's grievance process if denied. Confirm the current process with the specific Ohio Medicaid managed care plan, since Ohio administers Medicaid pharmacy benefits through multiple managed care organizations.

Commercial insurance in Ohio

Most commercial insurers use tiered formularies, and a brand-name, patent-protected sleep medication like Belsomra typically sits on a higher tier than generic alternatives, often with prior authorization or step therapy (trying and failing a generic first). This is a general pattern across commercial payers, not a fact specific to any named Ohio insurer's current formulary, and this draft does not have a verified, dated source confirming which specific Ohio insurers place Belsomra on which tier in 2026. Anyone comparing plans should pull the actual formulary document or call member services, since tier placement changes with each plan year.

Self-funded employer plans (governed by ERISA) are not bound by Ohio's state insurance mandates and may set their own rules, so an employee on a self-funded plan should check with the plan administrator directly rather than assume standard marketplace formulary terms apply.

The Merck savings card

Merck has offered a co-pay savings program for commercially insured Belsomra patients in the past. Savings card terms (dollar caps, first-fill offers, annual maximums) are set by the manufacturer and are revised periodically, and they typically exclude patients enrolled in Medicare, Medicaid, TRICARE, or other government-funded insurance. Because this program's specific current terms were not verified against Merck's official program page for this draft, readers should confirm the live terms directly through the manufacturer or their prescriber before counting on a specific savings figure.

Compounded suvorexant through Ohio 503A pharmacies

Compounded suvorexant is a distinct category from the FDA-approved Belsomra tablet, and the distinction matters for safety and expectations. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacy may compound a medication for an individual patient based on a valid prescription. Ohio compounding pharmacies are licensed and inspected by the Ohio State Board of Pharmacy, which enforces USP compounding standards.

Per FDA guidance on compounding, compounded drugs are not FDA-approved. They have not undergone the agency's review for safety, effectiveness, or manufacturing quality, and a compounded suvorexant product has not been shown bioequivalent to the FDA-approved tablet. Compounding is generally appropriate when a commercially available product does not meet a specific patient's medical need, for example a patient who cannot swallow tablets, rather than as a routine cost-saving substitute for a drug that is otherwise available and appropriate. Not every Ohio compounding pharmacy stocks suvorexant active ingredient, and prescribers should document the clinical reason for choosing a compounded product over the approved tablet.

Telehealth prescribing in Ohio

Ohio permits telehealth prescribing of Schedule IV controlled substances, including suvorexant, when the prescriber holds an active Ohio license (or practices under a valid interstate arrangement) and the encounter meets the state's requirements, which have generally required real-time, two-way audio-video contact rather than a message-only exchange. Federal telemedicine rules for prescribing controlled substances without a prior in-person visit have been in flux in recent years, with temporary flexibilities extended and revised multiple times. Because the current federal status of these flexibilities is date-sensitive and was not verified against a current DEA notice for this draft, confirm the live rule with the prescribing telehealth platform or the DEA's published guidance before relying on it.

How Belsomra's mechanism compares with older sleep drugs

Suvorexant was the first dual orexin receptor antagonist approved by the FDA, in August 2014, based on registration trials in patients with insomnia. The FDA label describes suvorexant's effect on sleep onset and maintenance and lists next-day somnolence as a labeled risk, particularly at the 20 mg dose; the label also notes that taking the drug with or shortly after a meal delays its effect. Readers who want the specific magnitude of benefit reported in the pivotal trials, or exact adverse-event rates, should pull those numbers from the FDA label itself rather than from a secondhand percentage, since this draft is not attaching specific trial statistics to an unverified journal citation.

Older generic sedative-hypnotics, such as zolpidem, eszopiclone, and off-label trazodone, work through a different mechanism (GABA-A receptor modulation, in the case of the Z-drugs) and are typically far less expensive because they are generic. That price gap, not a clinical inferiority, is the main reason insurers commonly require patients to try a generic option before approving a DORA. Cognitive behavioral therapy for insomnia (CBT-I) is recommended by sleep medicine guideline bodies as a first-line treatment for chronic insomnia and is covered by most Ohio insurance plans; it does not carry a drug cost at all once completed, though it requires a time investment the medication does not.

Evidence boundary: what is established versus what needs verification

Established: Suvorexant/Belsomra is FDA-approved for insomnia, is a Schedule IV controlled substance, has no FDA-approved generic version as of this writing, and carries a labeled risk of next-day somnolence. Compounded suvorexant is legal under 503A rules when tied to a valid individual prescription, but is not FDA-approved and has not been shown bioequivalent to the branded tablet. Ohio permits telehealth prescribing of Schedule IV drugs under state medical board rules.

Plausible but not verified in this draft: Specific current cash prices, specific insurer tier placements for named Ohio commercial plans, the exact current terms of the Merck savings card, and the precise structure of Ohio Medicaid's coverage restriction on suvorexant. These change often enough, and were not confirmed against a dated primary source, that printing an exact number here would risk being wrong the day it is read.

Not established: That compounded suvorexant performs equivalently to the FDA-approved tablet, and that any specific discount platform reliably beats pharmacy-negotiated cash prices in every Ohio market.

When to involve a prescriber or seek urgent care

Contact your prescriber before increasing your Belsomra dose on your own, combining it with alcohol or other sedatives, or switching to a compounded version without discussing the change. Seek urgent medical attention for signs of a severe allergic reaction, unusual sleep-related behavior (such as sleepwalking or engaging in activities with no memory of them the next day), or worsening depression or suicidal thoughts, all of which are reasons to stop the medication and get evaluated promptly rather than wait for a routine follow-up.

Verification checklist: stable facts versus facts you must confirm before paying

Use this checklist to distinguish between stable suvorexant information that will remain current and details that require verification before application.

Stable, verify rarely (federal and clinical facts):

• Suvorexant's FDA approval status and labeled indication, check the FDA label directly if in doubt.
• DEA Schedule IV classification.
• The 503A compounding framework and the fact that compounded drugs are not FDA-approved, see FDA compounding guidance.
• Ohio Board of Pharmacy oversight of compounding pharmacies, see pharmacy.ohio.gov.
• Standard dosing range (10 mg to a 20 mg maximum) as printed on the FDA label.

Volatile, verify before you pay or prescribe (date everything you find):

• Cash price at your specific Ohio pharmacy today.
• Your specific commercial plan's formulary tier and prior authorization or step-therapy requirement for the current plan year.
• Ohio Medicaid's or your managed care plan's current preferred drug list status for suvorexant.
• The Merck savings card's current eligibility rules and dollar caps, confirmed on the manufacturer's official program page.
• Whether a specific 503A pharmacy near you currently stocks suvorexant active ingredient.
• The current federal and Ohio rules on telehealth prescribing of controlled substances without a prior in-person visit.

If a number in any article, including this one, is not dated and sourced to the payer, pharmacy, or agency itself, treat it as a starting estimate rather than a quote you can act on.

This article is intended for general education about Belsomra (suvorexant) cost factors in Ohio and does not substitute for advice from your prescriber, pharmacist, or insurance plan. Pricing, coverage, and telehealth prescribing rules referenced above change frequently; verify current details before making a treatment or purchasing decision. This draft is pending qualified clinical and pharmacy review.